Biolife solutions stock.

The business earned $33.33 million during the quarter, compared to the consensus estimate of $33.28 million. BioLife Solutions has generated ($2.37) earnings per share over the last year (($2.37) diluted earnings per share). Earnings for BioLife Solutions are expected to grow in the coming year, from ($1.06) to ($0.26) per share.The BioLife Solutions stock price gained 3.76% on the last trading day (Friday, 24th Nov 2023), rising from $13.57 to $14.08. During the last trading day the stock fluctuated 11.10% from a day low at $12.79 to a day high of $14.21. The price has risen in 6 of the last 10 days and is up by 23.62% over the past 2 weeks.10 nov 2023 ... Byrnes covers the Healthcare sector, focusing on stocks such as Durect, Oncternal Therapeutics, and BioLife Solutions. According to TipRanks, ...Jun 26, 2020 · Hedge fund activity in BioLife Solutions, Inc. (NASDAQ:BLFS) Heading into the second quarter of 2020, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a change of ... Aug 9, 2021 · BOTHELL, Wash., Aug. 9, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton ...

You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.

On average, Wall Street analysts predict. that Biolife Solutions's share price could reach $25.50 by Aug 10, 2024. The average Biolife Solutions stock price prediction forecasts a potential upside of 103.84% from the current BLFS share price of $12.51.

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BOTHELL, Wash., Aug. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced financial results for the three and six months …If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...The business earned $33.33 million during the quarter, compared to the consensus estimate of $33.28 million. BioLife Solutions has generated ($2.37) earnings per share over the last year (($2.37) diluted earnings per share). Earnings for BioLife Solutions are expected to grow in the coming year, from ($1.06) to ($0.26) per share.

Hedge fund activity in BioLife Solutions, Inc. (NASDAQ:BLFS) Heading into the second quarter of 2020, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a change of ...

Total revenue for the third quarter of 2023 was $33.3 million, a decrease of $7.4 million, or 18%, from $40.7 million for the third quarter of 2022. There was no COVID related revenue in the third ...

BioLife Solutions, Inc. Owego, New York. We have audited the accompanying Balance Sheets of BioLife Solutions, Inc. as of December 31, 2006 and 2005, and the related Statements of Operations, Stockholders’ Equity and Cash Flows for the years then ended. These financial statements are the responsibility of the Company’s management.BOTHELL, Wash., Sept. 1, 2021 / PRNewswire / -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies ...On November 15, 2023, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $12.34 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was 10.28%, and its shares lost 41.93% of ...The evo DV10 Smart Shipper represents the best-in-class performance for cell and gene therapy logistics management. Designed to handle high-value payloads for long-haul international or bulk shipments, the performance is outstanding. With an internal temperature of ≤-180˚C, DV10 Smart Shipper can be upright or on its side during ...The estimated net worth of Sarah Aebersold is at least $571,339.17 as of July 24th, 2023. Ms. Aebersold owns 43,983 shares of BioLife Solutions stock worth more than $571,339 as of October 12th. This net worth evaluation does not reflect any other assets that Ms. Aebersold may own. Learn More about Sarah Aebersold's net worth.This report will help you with various insights regarding the recent year performance of BioLife Solutions Inc (BLFS) stock.View the latest BioLife Solutions Inc. (BLFS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

BOTHELL, Wash., March 22, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the signing of a definitive merger agreement to acquire Global Cooling, Inc., operating as …Maximize post-thaw cell recovery and viability following cryopreservation at low temperatures (-80°C to -196°C) with ready-to-use CryoStor® CS5. Serum-free, animal component-free, and cGMP-manufactured, this defined medium provides a safe, protective environment for cells and tissues during freezing and thawing processes and storage.Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.BioLife Solutions, Inc., Bothell, Washington. 194 likes · 5 talking about this · 7 were here. Class-defining solutions for bioproduction workflows.Culture supplement to replace FBS or AB Serum. Biodefined composition reduces lot-to-lot variability. Supports a wide range of cell types including MSCs, T-Cells, NK Cells, Endothelial cells, and more. Promotes improved in vitro and In vivo cell quality in CAR-T applications. Typically used at concentrations ranging from 2% to 10%.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.BioLife Solutions Stock Up 7.1 %. Shares of NASDAQ BLFS opened at $13.25 on Monday. BioLife Solutions, Inc. has a one year low of $8.92 and a one year high of $26.89. The company has a debt-to ...

On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...

BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) shares fell 4.2% during trading on Monday . The company traded as low as $13.37 and last traded at $13.49. 76,840 shares changed hands ...BioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services. Our tools portfolio includes our proprietary CryoStor® freeze media and ...Biolife Solutions releases figures for Q3 on November 9. Wall Street analysts predict losses per share of $0.364. Go here to track Biolife Solutions stock price in real-time ahead of earnings.Biolife Solutions Inc (NASDAQ: BLFS). Biolife Solutions has a current Value Trend Rating of C (High Neutral). This modestly high Value Trend Rating is derived from Biolife Solutions' very high Power Rating of 97 and low Appreciation Score of 18.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.BioLife Solutions is a class-defining cell and gene therapy bioproduction tools and services company. Our solutions give life science companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of biological materials. BioLife Solutions is one of Washington’s best places to work ...Dec 4, 2023 · Biolife Solutions Inc (NASDAQ:BLFS) has a beta value of 1.60 and has seen 2.24 million shares traded in the last trading session. The company, currently valued at $596.91M, closed the last trade at $13.25 per share which meant it gained $0.88 on the day or 7.11% during that session. The BLFS stock ... BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ...msn.com - November 17 at 10:30 PM. BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales Cycles. finance.yahoo.com - November 16 at 10:07 AM. Analysts Just Shaved Their BioLife Solutions, Inc. (NASDAQ:BLFS) Forecasts Dramatically. finance.yahoo.com - November 16 at 10:07 AM.

Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.

MAIN SITE. STORE. Solutions

Biolife Solutions releases figures for Q3 on November 9. Wall Street analysts predict losses per share of $0.364. Go here to track Biolife Solutions stock price in real-time ahead of earnings.The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.Dec 4, 2023 · Rhumbline Advisers decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report) by 8.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 80,251 shares of the medical equipment provider’s stock after selling 7,097 shares during the period. Rhumbline Advisers’ holdings in BioLife Solutions were worth $1,774,000 as of its most recent […] Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected], Wash., Aug. 9, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton ...Complete BioLife Solutions Inc. stock information by Barron's. View real-time BLFS stock price and news, along with industry-best analysis.Mar 23, 2023 · BioLife Solutions Reports Third Quarter 2023 Financial Results. BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene... Nov 02, 2023. BioLife Solutions is expected to report its next quarterly earnings on March 12, 2020. TrendSpider From a technical standpoint, the stock opened higher and closed sharply lower during Thursday's ...BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago.

The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Mar 16, 2023 · BioLife Solutions is reaffirming 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $188 million to $202 million ... BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ...Instagram:https://instagram. tesla model y price cutbloomberg commodities indexvz dividendsforex com leverage Mar 22, 2021 · BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ... Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services. battery stocks to buyearnings nvda Get the latest BioLife Solutions, Inc. (BLFS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the company's performance outlook, earnings date, dividend and yield, fair value, ratings and more.While BioLife Solutions, Inc. ( NASDAQ:BLFS) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the NASDAQCM, rising to highs ... discount futures trading Get a real-time BioLife Solutions, Inc. (BLFS) stock price quote with breaking news, financials, statistics, charts and more.The estimated net worth of Marcus Schulz is at least $465,171.85 as of August 25th, 2023. Mr. Schulz owns 42,097 shares of BioLife Solutions stock worth more than $465,172 as of November 2nd. This net worth approximation does not reflect any other investments that Mr. Schulz may own. Learn More about Marcus Schulz's net worth.Biolife Solutions will release earnings for Q1 on May 10. Wall Street predict expect Biolife Solutions will release losses per share of $0.213. Go here to watch Biolife Solutions stock price in ...